Posted on

MindMed Submits Application For NASDAQ Up-Listing, Appoints Canaccord Genuity As Financial Advisor

NEW YORK, Sept. 21, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF)(DE: MMQ), the leading drug development company for psychedelic inspired medicines, is evaluating an expanded United States investor base through an up-listing on the NASDAQ Capital Market (“NASDAQ”).

As part of this up-listing strategy in the United States, MindMed has submitted an application to list its subordinate voting shares on NASDAQ.  The listing of MindMed’s shares on NASDAQ will be subject to a number of regulatory requirements, including review of the company and acceptance for listing by NASDAQ. There can be no assurance that NASDAQ acceptance will be granted.

MindMed has appointed Canaccord Genuity Corp. (“Canaccord Genuity”) as financial advisor to assess the viability of a potential up-listing to NASDAQ and also help to evaluate M&A opportunities available to the company.

MindMed Co-Founder and Co-CEO JR Rahn said “The psychedelic medicine industry is maturing and expanding rapidly, and we want to grow with it. We look forward to working with Canaccord Genuity to evaluate the opportunity for an up-listing on NASDAQ and help us navigate M&A opportunities now available to the company.”

‍

About MindMed
Mind Medicine (MindMed) Inc. is a drug development company that discovers, develops, and deploys psychedelic inspired medicines to improve health, promote wellness, and alleviate suffering. The company is assembling a compelling drug development pipeline of innovative treatments through human clinical trials to help patients with mental and behavioral health issues, including substance use disorder. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co

‍

MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of MindMed, and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed’s ability to obtain approval for listing on NASDAQ; MindMed’s and its collaborators’ ability to continue to conduct research and clinical programs, MindMed’s ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, “Products”), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed’s Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed’s ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed’s collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed’s Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed’s business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management’s current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities of the company will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act)

‍

View the Official Press Release

Posted on

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

TORONTO, Sept. 21, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its psychedelics therapeutics programs specifically as it relates to the Company’s oral thin-film delivery system and clinical studies with psilocybin at the University of Wisconsin-Madison.

“We are expanding our product pipeline with a focus on psychedelic therapeutics incorporating our novel oral thin-film delivery technology with psilocybin, in which we have prototypes developed and we will move towards clinical studies with the University of Wisconsin-Madison along with other key industry partners,” said Michael Frank, CEO of Revive. “In addition, we are advancing our Phase I clinical study to evaluate the safety and feasibility of psilocybin in adults with Methamphetamine Use Disorder. Our initiatives in product development and clinical studies gives us a leading position in the psychedelic space.”

Psilocybin Oral Thin-film Product

Under its sponsored research partnership with the Reed Research Group out of the University of Wisconsin-Madison, the Company is developing its tannin-chitosan composite of orally dissolvable thin films which offers a unique delivery platform for therapeutic doses (1-20mg) of psilocybin into the oral cavity. The Company has received its final set of prototypes and is preparing to scale for manufacturing for future clinical studies involving psilocybin and other psychedelic-derived medicines. There are a number of advantages and benefits of an orally dissolvable psilocybin thin film such as the rapid dissolving and onset of action to the bloodstream, the ease and convenience for patients to administer without the need of water, chewing or swallowing, the potential of improved therapeutic outcomes and efficacy for underserved diseases and disorders including the flexibility to create accurate dosing and tasteful options.The Company’s delivery technology is a natural, non-toxic, biodegradable and biocompatible composite that combines a tannin material, which is derived from a plant group having antibacterial, antifungal, antioxidant and wound healing properties, and a chitosan material, which is derived from the crustacean group having blood-clotting and antimicrobial properties. The delivery technology has a rapid onset of action and controlled or sustained release potential capabilities and may allow combining multiple extracts from mushrooms in one formulation.

Clinical Study of Psilocybin in the Treatment of Methamphetamine Use Disorder

The Company recently announced that it has entered into a Clinical Trial Agreement with the Board of Regents of the University of Wisconsin System to conduct a clinical study entitled “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.” The Phase I study Principal Investigator is Dr. Christopher R. Nicholas, Ph.D., Assistant Professor of Program for Research Outreach Therapeutics and Education in the Addictions in the Department of Family Medicine and Community Health at University of Wisconsin School of Medicine and Public Health. The clinical study will be conducted at the University of Wisconsin-Madison, School of Medicine and Public Health, and School of Pharmacy, which holds a Wisconsin special authorization and DEA license to perform clinical research with psilocybin. The Company will have exclusive access to key intellectual property from this study.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com 
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

Posted on

Psychedelics and Their Place in Modern Pharmacology, a Q&A with Andrew Hegle, Ph.D.

Dr. Andrew Hegle currently serves as Entheon Biomedical’s Director of Operations. He has been an adjunct professor of Pharmacology at the University of British Columbia since 2015. He has a background in molecular biology and biochemistry and has published research investigating membrane receptor proteins’ role in physiology, behaviour and disease. He was a co-founder of both Cannevert Therapeutics and Canalytic Laboratories in Vancouver. Andrew is responsible for putting all of the elements needed for Entheon to commence clinical trials. This involves planning, timelines, budgets, protocols for the drug development process, working with clinicians and more.  

Tell me about your background and why you chose to work with Entheon Biomedical.

I did my Ph.D. in Molecular Biology at the University of Michigan before coming to Vancouver in 2007. I then spent six years working at the University of British Columbia (UBC) researching cardiovascular health, genetics, and neuroscience. I then decided to move away from academia and began working on a startup company in the cannabis space focused on pain relief, and even with all of the hype that there was in the sector, what was important to us was putting the science behind it and setting up clinical trials. I spent about five years doing that while getting involved with UBC’s pharmacology department before joining Entheon.

There seems to be an increasing amount of interest in the psychedelic therapy field now. Why do you think that is?

Firstly, I am a big believer in psychedelics’ therapeutic potential, and I believe that the increasing interest in the area is due to a confluence of things. Certainly, the decriminalization and reassessment of cannabis use for therapeutic purposes broke down some taboos around psychoactive drugs and their possibilities. But more generally, I think that because we live in a more connected world, people can more easily learn about how diverse cultures approach things. Consider, for example, how ayahuasca is understood and used in South America, which is in stark contrast to the war on the United States’ drug culture.

And at the same time, society is in the midst of a mental health crisis, and there is a desperate need for new tools to combat this. Incidence of depression, loneliness, and dependence on substances like opioids are all at an all-time high. In this urgent crisis, I think that psychedelics are a prominent tool that we should be leveraging for mental health treatments. We already know these drugs have many potential benefits, but no one has fully explored their potential in the clinic until recently. Steven Barker described this research as “forbidden fruit long ripening on the tree of knowledge,” which I think is a great metaphor.

Are psychedelics Cannabis 2.0?

I don’t really like this comparison because I think it’s very different. It’s genuinely apples and oranges. I can certainly understand that these could be put into a similar category and thought of as street drugs in the average person’s mind. But I believe that the therapeutic benefit that psychedelics have compared to cannabis will be much more impactful.

Why does DMT interest you in particular?

DMT is an endogenous molecule, meaning that it’s in our brains already. It wasn’t invented in a lab; our bodies naturally do so, so it’s not poison. When new drugs are created from scratch, we often don’t know what kinds of side effects they may have, so it’s exciting to work with an endogenous molecule because we already know that it has a good safety profile.

DMT is fascinating because it is a very simple molecule that can be metabolized quickly and isn’t complicated. We don’t have to worry about by-products or different metabolic artifacts that other drugs might have.

How important is an integrated approach with psychedelic therapy? 

With psychedelics, it’s not just about the drug, it is everything around it too. The setting and the patient’s mental state are crucial, including psychotherapy and working with a therapist for multiple hours before and after so you can make sense of what has happened. It isn’t like most drugs where you develop it, improve it, and your doctor sends you home with it. It is an entirely different paradigm.

I see these substances being successful with addiction, treatment-resistant depression and a range of other issues. But it must be done with supervision in a clinic. That said, you don’t want to do it in a sterile hospital room with beeping machines and white walls. You have to have it in the right space, with therapy and with an integrative approach. And this is the kind of reality for which Entheon is developing tools.

See the entire Entheon team.

Posted on

COMPASS Pathways announces pricing of upsized initial public offering

COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the pricing of its upsized initial public offering in the United States of 7,500,000 American Depositary Shares (“ADSs”) representing 7,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for total gross proceeds of $127.5 million. All ADSs sold in the offering were offered by COMPASS. The ADSs are expected to begin trading on the Nasdaq Global Select Market on September 18, 2020 under the ticker symbol “CMPS.” The offering is expected to close on or about September 22, 2020, subject to the satisfaction of customary closing conditions. In addition, COMPASS has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 ADSs at the initial public offering price, less underwriting discounts and commissions.

Cowen, Evercore ISI and Berenberg are acting as joint book-running managers for the offering. Canaccord Genuity is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.

A registration statement relating to these securities has been filed with the US Securities and Exchange Commission (the “SEC”) and became effective on September 17, 2020. The offering will be made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Attention: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, New York 10055, telephone: (888) 474-0200, or email: ecm.prospectus@evercore.com; or Berenberg Capital Markets LLC, Attention: Investment Banking, 1251 Avenue of the Americas, 53rd Floor, New York, New York 10020, or by telephone at +1 (646) 949-9000, or by e-mail at prospectusrequests@berenberg-us.com. For the avoidance of doubt, such prospectus will not constitute a “prospectus” for the purposes of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and will not have been reviewed by any competent authority in any EU member state or the UK.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

For readers in the European Economic Area (“EEA”) and the UK
In any EEA member state and the UK (each, a “Relevant State”), this press release and any offering are only addressed to and directed at persons who are qualified investors (“Qualified Investors”) in that Relevant State within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.

For readers in the UK
In the UK, this press release, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended (the “FSMA”), and any offering are only addressed to and directed at Qualified Investors (i) who are investment professionals as described in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) persons and entities who fall within Article 49(2)(a) to (d) of the Order, or (iii) to whom it may otherwise lawfully be communicated (all such persons being referred to as “relevant persons”).

This press release must not be acted on or relied on (i) in the UK, by persons who are not relevant persons, and (ii) in any EEA member state, by persons who are not Qualified Investors. Any investment or investment activity to which this press release relates is available only to and will only be engaged with (i) in the UK, relevant persons, and (ii) in any EEA member state, Qualified Investors. This press release does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of the FSMA or otherwise.

 

About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we are currently conducting a phase IIb clinical trial of psilocybin therapy for TRD, in 20 sites across Europe and North America. We are headquartered in London, UK, with offices in New York, USA. Our vision is a world of mental wellbeing.

 

Forward-looking statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding COMPASS’s expectations regarding the commencement of trading of its ADSs on the Nasdaq Global Select Market, the completion and timing of the closing of the offering and the anticipated gross proceeds from the offering. Forward-looking statements are based on COMPASS’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the satisfaction of customary closing conditions and the completion of the offering, and the risks inherent in mental health care clinical trials. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the final prospectus related to the offering to be filed with the SEC. Forward-looking statements contained in this announcement are made as of this date, and COMPASS undertakes no duty to update such information except as required under applicable law.

 

Enquiries

Tracy Cheung, tracy@compasspathways.com, +44 7966 309024
Amy Lawrence, amy@compasspathways.com, +44 7813 777919

Posted on

AIkido Pharma Announces Update On Its Use Of Artificial Intelligence

Development of Products, Tools, and Technologies to Accelerate Development of Key Marker Panels for the Personalized Treatment of PDA

NEW YORK, Sept. 18, 2020 /PRNewswire/ — AIkido Pharma Inc. (Nasdaq: AIKI) today announced that its work with research partner, Cogia BioTech LTD (www.cogia.de), has delivered several key updates on efforts to accelerate the study of PDA (Pancreatic Ductal Adenocarcinoma) treatments. As previously reported, the Company executed a Scientific Research Agreement with The University of Texas Southwestern Medical Center and Cogia to use machine learning to find genetic markers in people that indicate an increased risk of developing pancreatic cancer.

(PRNewsfoto/AIkido Pharma Incorporated)

Cogia Biotech, a Big-data, Artificial Intelligence (AI), and Machine Learning (ML) software company committed to using powerful AI engines and algorithms to develop compelling outcomes in drug development, released a comprehensive progress report to AIkido which included:

  • The identification of clusters of markers that interact in signaling pathways affecting PDA survival.
  • The development of products and tools to provide extensive information on PDA markers to guide personalized medicine.
  • The assembly of survival associations of individual markers from ONCOLNC.org into sets that will help identify novel targets in PDA.
  • Information about gene and protein function in human PDA patients and human PDA cancer cell lines to help prioritize individual diagnostic markers.

Anthony Hayes, CEO of AIkido stated, “We are extremely pleased with the progress that Cogia has made in this research project, and are enthusiastic about their continued efforts to develop panels of markers that will rapidly identify patients who have initiated early events in pancreatic cancer. Cogia’s Diagnostic Assay Application and Prognostic Marker Characterization Application products assemble essential information on antibodies specific to the respective proteins for more than 20,000 antibody reagents and utilizes the unsupervised learning protocols of the Cogia AI/ML engine to identify clusters of similarly expressed genes, and their association with PDA subtypes.  These tools establish the building blocks of what we continue to believe will be an even broader set of usable full-service products and tools for ongoing and more expanded PDA diagnostics, prognostics, and therapeutics.

About AIkido

AIkido was initially formed in 1967 and is a biotechnology company with a diverse portfolio of small-molecule anti-cancer therapeutics.  The Company’s platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and Wake Forest University. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). In addition, we are constantly seeking to grow our pipeline to treat unmet medical needs in oncology.  The Company is also developing a broad spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Contact:

Investor Relations:

Hayden IR
Brett Maas, Managing Partner
Phone: (646) 536-7331
Email: brett@haydenir.com
www.haydenir.com

AIkido:

Phone: 212-745-1373
Email: investorrelations@AIkido.com
www.AIkido.com

 

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/aikido-pharma-announces-update-on-its-use-of-artificial-intelligence-301133942.html

SOURCE AIkido Pharma Inc.

News Provided by PR Newswire via QuoteMedia

Posted on

Numinus Announces Listing of Warrants

VANCOUVER, BC, Sept. 18, 2020 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company“) (TSXV: NUMI), a company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapy, is pleased to announce that the TSX Venture Exchange (“TSXV“) has accepted for listing the 9,200,000 warrants (the “Warrants“) issued pursuant to the Company’s previously announced prospectus offering that closed on September 10, 2020.

The Warrants will be listed for trading on the TSXV under the symbol “NUMI.WT” effective at market open on Monday, September 21, 2020.

Each Warrant entitles the holder thereof to acquire one common share of the Company at an exercise price of $0.35 until September 10, 2022. The Warrants were issued pursuant to, and are governed by, a warrant indenture between the Company and Computershare Trust Company of Canada dated September 10, 2020.

About Numinus

Numinus is a Vancouver-based health care company creating an ecosystem of health solutions centred around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted therapies. Numinus’ ecosystem units include Numinus Bioscience, Numinus R&D, and Numinus Health. Each unit is undertaking distinct, synergistic initiatives to hasten legal, for-profit psychedelic-assisted therapy models in Canada and position Numinus as a trusted industry leader for the eventual regulated rollout of these therapies once available. Numinus Bioscience includes a 7,000 square foot research and testing laboratory as well as numerous Health Canada licenses (through its wholly-owned subsidiary Salvation Botanicals) including a cannabis testing licence used for sustainable revenue to support the company’s psychedelic efforts. The company holds a dealers licence which allows it to import, export, possess, and test MDMA, psilocybin, psilocin, DMT and mescaline. Numinus is the only publicly listed company in Canada to be issued a Health Canada license to produce and extract psilocybin from mushrooms. These licences will allow Numinus to support the growing number of studies on the potential benefits of psychedelic therapies through research projects, product development, and the supply and distribution of these substances. Numinus R&D leverages established relationships to position the Company for partnerships to host studies, develop medical and therapeutic protocols, and influence regulatory approval. Numinus Heath is dedicated to delivering therapies that enhance and supplement existing options for people wanting lasting physical, mental and emotional health — with psychedelic treatments at its core when approved for therapeutic and research use. For more information, visit www.numinus.ca.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

ON BEHALF OF THE BOARD OF NUMINUS WELLNESS INC.

Payton Nyquvest
President, Chief Executive Officer and Chair

Further information about the Company is available under its profile on the SEDAR website, www.sedar.com, and on the Company’s website.

For further information: Stacey Wallin, Chief Strategy Officer, 1.833.686.4687

Posted on

BETTER PLANT ANNOUNCES WRIGHT & WELL PACKAGING ACCLAIMED BY LEADING DESIGN PUBLICATIONS

Vancouver, B.C. – September 17, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that subsidiary Wright & Well, which creates high-end THC and CBD infused topicals and tinctures, has been recognized by two leading publications for it’s packaging design.

Packaging of the World and The World of Brand Design Society have featured Wright & Well’s packaging online. Packaging of the World is one of the most prominent package design websites showcasing the most interesting and creative work worldwide. The World Brand Design Society is the home of consumer and corporate brand design.

“When we were designing the Wright & Well packaging, we wanted to convey quality, elegance and wellness, while making the unboxing experience unique and memorable,” said Perry Chua, Creative Director for Better Plant Sciences. “It is an honour to be recognized by these publications in the packaging design industry.”

Wright & Well consists of an Ayurveda-inspired collection of THC- and CBD-infused products. Using high quality Cannabis Sativa (Hemp) Root Oil, crafted through an exclusive proprietary extraction process, Wright & Well’s first five products include 2 CBD tinctures regular and extra strength, an analgesic topical gel, pain balm and massage oil. The products are currently sold in Oregon through licensed distributor Nova Paths.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

HAVN LIFE SCIENCES ANNOUNCES LISTING APPROVAL ON THE FRANKFURT STOCK EXCHANGE

Havn Life is now cross-listed and trades on both the CSE & FSE 

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it has been accepted to list its common shares on the Frankfurt Stock Exchange (FSE) under the trading symbol (5NP). The Company’s shares are now cross-listed on the Canadian Securities Exchange (CSE) and the FSE.

“We have been exceptionally fortunate to have received investment inquiries internationally in such a small period of time,” says Tim Moore, Co-CEO of Havn Life. “Our team has been moving quickly to make Havn Life’s common shares available to European investors. The team will continue to work towards making our shares available to investors globally.”

On Behalf of The Board of Directors
Susan Chapelle & Tim Moore
Co-CEOs

About Havn Life Sciences Inc.

Havn Life Sciences is a biotechnology company on a mission to unlock human potential using evidence-informed research. The Company is focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi, and the development of natural health care products from non-regulated compounds. Learn more at: havnlife.com and follow us on Facebook, Twitter and Instagram.

Connect

Investor Relations
ir@havnlife.com
604 (687)-7130

Facebook: @havnlife
Twitter: @havnlife
Insta: @havn.life
LinkedIn: @Havn Life

Media Contact
Brittany@exvera.com
778-238-6096

Posted on

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

TORONTO, Sept. 16, 2020 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillamine in the treatment of COVID-19 received approval from the independent Institutional Review Board (“IRB”). The EAP for compassionate use is a multi-center, open label study of Bucillamine in hospitalized patients with severe COVID-19 and is being done to complement the Company’s Phase 3 COVID-19 study in the U.S.  Revive expects to have patients enrolled in the United States this month.

“With the IRB approval of the expanded access protocol by Advarra, a premier IRB services company in North America, hospitalized patients with severe COVID-19 may access Bucillamine under the FDA compassionate use program under medical supervision by their physician,” said Michael Frank, Revive’s Chief Executive Officer. “The EAP serves as an option for patients that are not eligible for inclusion criteria in our Phase 3 clinical study in COVID-19 and the resulting data from the EAP will be valuable in supporting our clinical development of Bucillamine.”

The EAP for compassionate use provides physicians with access to Bucillamine under Revive’s existing Investigational New Drug (“IND”) application for COVID-19.  According to the FDA, expanded access is a potential pathway for a patient with an immediately life-threatening condition or serious disease or condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.

About the Expanded Access Study

The expanded access study is titled, “Multi-Center, Open-Label, Expanded Access Study of Bucillamine in Hospitalized Patients with Severe COVID-19 (EA-ARISE)”.  Patients will receive Bucillamine 200 mg orally, 3 times a day (TID), for up to 14 days. The objective is to monitor the safety and efficacy of Bucillamine (600 mg/day) and any clinical symptoms when administered up to 14 days in hospitalized patients with severe COVID-19.  Following completion of the treatment course, follow up safety assessments will be performed by a study nurse 14 and 42 days following the end of treatment.

The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.

Scientific Rationale of Bucillamine for COVID-19

Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV-2 infection in the lungs and attenuate the clinical course of COVID-19.

About Revive Therapeutics Ltd.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. Currently, the Company is exploring the use of Bucillamine for the potential treatment of infectious diseases, with an initial focus on severe influenza and COVID-19. With its recent acquisition of Psilocin Pharma Corp., Revive is advancing the development of Psilocybin-based therapeutics in various diseases and disorders. Revive’s cannabinoid pharmaceutical portfolio focuses on rare inflammatory diseases and the company was granted FDA orphan drug status designation for the use of Cannabidiol (CBD) to treat autoimmune hepatitis (liver disease) and to treat ischemia and reperfusion injury from organ transplantation. For more information, visit www.ReviveThera.com.

For more information, please contact:

Michael Frank
Chief Executive Officer
Revive Therapeutics Ltd.
Tel: 1 888 901 0036
Email: mfrank@revivethera.com
Website: www.revivethera.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Revive’s current belief or assumptions as to the outcome and timing of such future events. Forward looking information in this press release includes information with respect to the Offering, including the intended use of proceeds. Forward-looking information is based on reasonable assumptions that have been made by Revive at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Revive is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Reference is made to the risk factors disclosed under the heading “Risk Factors” in the Company’s annual MD&A for the fiscal year ended June 30, 2019, which has been filed on SEDAR and is available under the Company’s profile at www.sedar.com.

References

1. S Ye et al, Inhibition of Reactive Oxygen Species Production Ameliorates Inflammation Induced by Influenza A Viruses via Upregulation of SOCS1 and SOCS3., American Society for Microbiology. 2015 Mar;89(5):2672-2683).

2. L. Carati et al, Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment., Eur Respir J. 1997 Jul;10(7):1535-41).

3. M Mata et al, N-acetyl-L-cysteine (NAC) inhibit mucin synthesis and pro-inflammatory mediators in alveolar type II epithelial cells infected with influenza virus A and B and with respiratory syncytial virus (RSV)., Biochem Pharmacol. 2011 Sep;82(5):548-55.

4. D Ungheri et al, Protective effect of n-acetylcysteine in a model of influenza infection in mice., Int J Immunopathol Pharmacol. 2000 Sep-Dec;13(3):123-128.

5. RH Zhang et al, N-acetyl-l-cystine (NAC) protects against H9N2 swine influenza virus-induced acute lung injury., Int Immunopharmacol. 2014 Sep;22(1):1-8).

6. LD Horwitz, Bucillamine: a potent thiol donor with multiple clinical applications, Cardiovasc Drug Rev. 2003 Summer;21(2):77-90).

Posted on

Minnesota Medical Solutions’ Cannabis Patient Centers Rebranded to Green Goods™

MinnMed will become Vireo Health of Minnesota as the Company rebrands its retail locations to help better serve Minnesota’s medical cannabis patients

MINNEAPOLIS, Sept. 15, 2020 /PRNewswire/ — Vireo Health International Inc., (“Vireo” or the “Company”) (CNSX: VREO; OTCQX: VREOF), a leading physician-founded, science-focused multi-state cannabis company, today announced that Minnesota Medical Solutions (MinnMed), the company’s subsidiary in Minnesota, has changed its name to Vireo Health of Minnesota and its cannabis patient centers are in the process of being renovated and rebranded. The retail locations will now be called Green Goods.

Vireo Health of Minnesota's cannabis patient centers in Minneapolis, Bloomington, Rochester, and Moorhead will now be called Green Goods, as part of Vireo Health's growing network of locations nationwide.

The Company’s existing cannabis patient centers in Minneapolis, Bloomington, Rochester, and Moorhead are being improved and renovated to help create a best-in-class patient experience. The renovations will create a relaxed and engaging environment that helps streamline the process of purchasing medical cannabis products to help serve more patients in a timely fashion. The rebranding and exterior renovations are nearly complete and interior updates are ongoing at all existing locations.

Vireo Health of Minnesota expects to open two new locations in Blaine and Hermantown under the Green Goods brand by November of this year, with an additional two locations in Burnsville and Woodbury expected to be open by the end of 2020.

“The Green Goods brand is the next evolution of Vireo’s continued commitment to providing patients with best-in-class medical cannabis products and customer experiences,” said Kyle Kingsley, MD, CEO and Founder of Vireo Health. “The new renovated locations will both allow us to better serve patients and transform how we interact with local communities and employees.”

Building on the Company’s commitment to putting patients first, Green Goods locations will offer an inviting atmosphere that provides personalized service and wellness programs. Each location will also feature a ‘knowledge bar’ for patients seeking expert information and on-site pharmacists to help guide patients through their medical cannabis journey. The renovated shops will also be used for community engagement events, charitable giving programs, and educational outreach efforts.

Green Goods will continue to provide the same quality medical cannabis products and expert service to patients. Products will be repackaged under the Vireo Health brand, but nothing else about the products offered will change – the formulas, prices, and application formats will remain the same. Each Green Goods location will offer Vireo Health of Minnesota’s full range of pharmaceutical-grade cannabis products.

To learn more about Vireo Health of Minnesota and Green Goods retail locations, please visit www.minnmed.com.

About Vireo Health International, Inc.

Vireo Health International, Inc. (“Vireo” or the “Company”) is a physician-led cannabis company focused on bringing the best of technology, science, and engineering to the cannabis industry. Vireo manufactures proprietary, branded cannabis products in environmentally-friendly, state-of-the-art greenhouses and distributes its products through its growing network of Green GoodsTM retail dispensaries and through hundreds of third-party dispensaries in seven states. Vireo’s team of more than 400 employees, led by scientists, engineers, and cultivation experts, is focused on efficiency and the creation of best-in-class products, while driving scientific innovation within the cannabis industry and developing meaningful intellectual property. Today, Vireo is licensed to grow and/or process cannabis in 9 markets. The Company is operational in 7 of those 9 markets – including the core markets of Arizona, Maryland, Minnesota, New Mexico, and New York. The Company holds 32 total retail dispensary licenses, of which 13 are currently open for business.  For more information about Vireo Health, please visit www.vireohealth.com.

Contact Information

Media Inquiries
Albe Zakes
Vice President, Corporate Communications
albezakes@vireohealth.com
(267) 221-4800

Investor Inquiries
Sam Gibbons
Vice President, Investor Relations
samgibbons@vireohealth.com
(612) 314-8995

CisionView original content to download multimedia:http://www.prnewswire.com/news-releases/minnesota-medical-solutions-cannabis-patient-centers-rebranded-to-green-goods-301130887.html

SOURCE Vireo Health International, Inc.